Enveda
AmericasAI biotech startup Enveda valued at $2 billion, backed by former J&J CEO, planning to advance drug candidates into late-stage trials
curated · 2026-09-23 · context →
Enveda announced Phase 1 clinical trial results for ENV-308, an oral drug candidate designed to suppress appetite and preserve lean muscle mass by mimicking lactate phenylalanine. Positioned as first leptin sensitizer pill addressing GLP-1 side effects.
curated · 2026-08-18 · context →
